Strategic Partnerships Fibralign has a history of distributor and collaboration activity, including a Terumo distribution agreement in 2020 and ongoing global uptake with 18 countries. This suggests sales opportunities through regional distributors, hospital networks, and multi-national medical device distributors.

Clinical Validation BioBridge has achieved 510(k) clearance, CE mark, and KFDA approval, with presentations at major lymphology events. Leverage these milestones to approach surgical centers and wound/lymphedema clinics emphasizing regulatory readiness and proven clinical use.

Clinical Adoption Active engagement with leading surgeons across 18 countries and recent ISL congress updates indicate growing clinical adoption. Target high-volume centers and key opinion leaders for expansion, training programs, and bundled product offerings.

Funding & Scale Current revenue is under $1M with modest funding, signaling an opportunity to position BioBridge as a scalable solution for lymphatic repair. Propose bundled procurement, volume pricing, and international expansion packages to accelerate revenue growth.

Growth Channels As a Stanford spin-out with StartX and Rosenman Institute affiliations, there are valuable ecosystem channels for partnerships, pilot programs, and investor introductions. Leverage these networks to unlock co-development deals, grant-supported studies, and joint marketing.